Published in Curr HIV/AIDS Rep on June 01, 2012
A novel acute HIV infection staging system based on 4th generation immunoassay. Retrovirology (2013) 1.24
Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr (2013) 0.95
Risk patterns preceding diagnosis among newly HIV-diagnosed men who have sex with men in New York City. AIDS Patient Care STDS (2013) 0.88
Evaluation of a Rapid Point of Care Test for Detecting Acute and Established HIV Infection, and Examining the Role of Study Quality on Diagnostic Accuracy: A Bayesian Meta-Analysis. PLoS One (2016) 0.83
Dendritic Cell-Based Immunotherapies to Fight HIV: How Far from a Success Story? A Systematic Review and Meta-Analysis. Int J Mol Sci (2016) 0.75
Acute HIV infection presenting as hemophagocytic syndrome with an unusual serological and virological response to ART. BMC Infect Dis (2016) 0.75
A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection. PLoS One (2015) 0.75
Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain. J Virus Erad (2015) 0.75
Improving the Quality of Diagnostic Studies Evaluating Point of Care Tests for Acute HIV Infections: Problems and Recommendations. Diagnostics (Basel) (2017) 0.75
Knowledge and preferences concerning acute HIV testing programs among both Peruvian men who have sex with men and transgender women. Int J STD AIDS (2017) 0.75
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 7.68
HIV-1 transmission, by stage of infection. J Infect Dis (2008) 6.57
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med (2001) 5.89
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
Acute human immunodeficiency virus type 1 infection. N Engl J Med (1998) 5.04
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Role of the primary infection in epidemics of HIV infection in gay cohorts. J Acquir Immune Defic Syndr (1994) 4.81
A controlled trial of zidovudine in primary human immunodeficiency virus infection. N Engl J Med (1995) 3.89
Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med (2001) 3.80
The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 3.75
Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis (2006) 3.72
Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2000) 3.66
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
HIV-1 drug resistance in newly infected individuals. JAMA (1999) 3.49
Viral dynamics of acute HIV-1 infection. J Exp Med (1999) 3.45
Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: a case series. Ann Intern Med (1999) 3.37
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med (2006) 3.09
Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med (2011) 2.99
A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis (2006) 2.88
How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? AIDS (2007) 2.77
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med (2004) 2.64
Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS (2010) 2.62
Natural history of HIV-1 cell-free viremia. JAMA (1995) 2.58
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS (2001) 2.42
Feasibility of pooling sera for HIV-1 viral RNA to diagnose acute primary HIV-1 infection and estimate HIV incidence. AIDS (2000) 2.37
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines. Clin Infect Dis (2011) 2.30
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis (2011) 2.26
No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS (2008) 2.04
Risk factors and clinical presentation of acute primary HIV infection in India. JAMA (1997) 2.02
Primary HIV infection as source of HIV transmission within steady and casual partnerships among homosexual men. AIDS (2004) 1.82
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82
Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr (2006) 1.66
Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr (2009) 1.46
Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody. J Clin Microbiol (2001) 1.46
Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis (2006) 1.42
Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr (2009) 1.41
Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS (2002) 1.40
HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS (2010) 1.38
State of the art for diagnosis of HIV infection. Clin Infect Dis (2007) 1.34
The effect of pair formation and variable infectivity on the spread of an infection without recovery. Math Biosci (1998) 1.32
Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One (2011) 1.24
Acute primary HIV infection. JAMA (1997) 1.22
Sexually acquired HIV infections in the United States due to acute-phase HIV transmission: an update. AIDS (2009) 1.22
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine (2009) 1.21
Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. Antivir Ther (2009) 1.20
Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis (1993) 1.17
Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification. J Clin Microbiol (2010) 1.16
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. AIDS (2002) 1.14
Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med (2009) 1.13
Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol (2006) 1.11
Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIDS (2007) 1.10
Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS (2008) 1.04
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clin Infect Dis (2007) 1.02
HIV antiretroviral treatment: early versus later. J Acquir Immune Defic Syndr (2005) 0.99
Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis (1998) 0.99
Performance evaluation of the new fully automated human immunodeficiency virus antigen-antibody combination assay designed for blood screening. Transfusion (2008) 0.97
Dendritic cells loaded with HIV-1 p24 proteins adsorbed on surfactant-free anionic PLA nanoparticles induce enhanced cellular immune responses against HIV-1 after vaccination. Vaccine (2009) 0.89
Cost-effectiveness of earlier initiation of antiretroviral therapy for uninsured HIV-infected adults. Am J Public Health (2001) 0.87
Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study. AIDS (1995) 0.86
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection. J Infect Dis (2010) 0.85
Nanochemistry-based immunotherapy for HIV-1. Curr Med Chem (2007) 0.82
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med (2004) 9.11
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr (2006) 3.24
Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med (2006) 3.09
A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis (2006) 2.88
Evidence of dysregulation of dendritic cells in primary HIV infection. Blood (2010) 2.39
Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection. J Infect Dis (2011) 2.34
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals. J Infect Dis (2011) 2.26
Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection. J Virol (2006) 2.19
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science (2014) 2.11
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A (2007) 2.04
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med (2011) 1.97
Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis (2003) 1.90
Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82
Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J Virol (2007) 1.81
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis (2013) 1.78
Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr (2006) 1.66
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51
Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog (2009) 1.49
Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS (2007) 1.44
Predictors of response to highly active antiretroviral therapy. AIDS Read (2006) 1.41
Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol (2004) 1.40
Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS (2002) 1.40
Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. J Clin Invest (2011) 1.37
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr (2013) 1.31
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS (2003) 1.30
Transmission and long-term stability of compensated CD8 escape mutations. J Virol (2008) 1.29
Colonization and subsequent skin and soft tissue infection due to methicillin-resistant Staphylococcus aureus in a cohort of otherwise healthy adults infected with HIV type 1. J Infect Dis (2009) 1.28
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother (2009) 1.27
Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog (2012) 1.26
Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir Ther (2004) 1.23
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection. PLoS One (2010) 1.21
Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs (2008) 1.18
Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection. J Virol (2003) 1.15
Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci (2004) 1.14
Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. Drugs Today (Barc) (2007) 1.13
The gastrointestinal tract is critical to the pathogenesis of acute HIV-1 infection. J Allergy Clin Immunol (2005) 1.09
Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure. J Virol (2002) 1.05
Function of NKT cells, potential anti-HIV effector cells, are improved by beginning HAART during acute HIV-1 infection. Int Immunol (2007) 1.03
Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One (2010) 1.01
Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy. J Virol (2003) 0.98
Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofovir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. J Acquir Immune Defic Syndr (2008) 0.96
Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). J Acquir Immune Defic Syndr (2012) 0.93
Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection. J Virol (2004) 0.93
Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity. J Virol (2012) 0.93
The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math Biol (2003) 0.93
Goals and milestones during treatment of HIV-1 infection with antiretroviral therapy: a pathogenesis-based perspective. Antiviral Res (2002) 0.91
In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression. J Acquir Immune Defic Syndr (2008) 0.90
Comparison of algorithms that interpret genotypic HIV-1 drug resistance to determine the prevalence of transmitted drug resistance. AIDS (2008) 0.89
Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr (2012) 0.89
Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches. Curr Opin Investig Drugs (2006) 0.87
Novel integrase inhibitors for HIV. Expert Opin Investig Drugs (2010) 0.86
Single genome analysis reveals genetic characteristics of Neuroadaptation across HIV-1 envelope. Retrovirology (2014) 0.84
Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs (2003) 0.84
Identifying the early post-HIV antibody seroconversion period. J Infect Dis (2011) 0.82
Duration of an intermittent episode of viremia. Bull Math Biol (2005) 0.82
Next-generation integrase inhibitors : where to after raltegravir? Drugs (2013) 0.81
Early immune adaptation in HIV-1 revealed by population-level approaches. Retrovirology (2014) 0.79
Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS (2006) 0.78
Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection. AIDS (2016) 0.77
GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1. J Acquir Immune Defic Syndr (2015) 0.76
Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant. J Acquir Immune Defic Syndr (2015) 0.76
The Relationship Between Injection Drug Use Risk Behaviors and Markers of Immune Activation. J Acquir Immune Defic Syndr (2016) 0.75
HIV-1 viral dynamics studies in the setting of clinical trials--A window of opportunity. J Infect Dis (2007) 0.75
Cabotegravir long-acting injection protects macaques against intravenous challenge with SIVmac251. AIDS (2016) 0.75
Monoclonal antibodies to host cellular receptors for the treatment and prevention of HIV-1 infection. Curr Opin HIV AIDS (2015) 0.75
Sustained viremia during highly active antiretroviral therapy with accelerated proviral DNA decay in the setting of infection with syphilis. AIDS (2003) 0.75
Acute HIV-1 infection: past lessons, current thinking, future goals. Curr Opin HIV AIDS (2008) 0.75